If there is absolute improvement the reduction percentage will be greater than 100. Let's worry about that when we get there. It will be explained.
Personally, I think the odds are we don't see a mean absolute improvement, but instead a very slight decline. However, genetic variables should create a pretty wide response range, especially compared to downstream mabs. Those should have fewer variables: The plaques are the same substance, the mab is the same substance, that interaction -- other than perhaps levels of inflammation -- should be the essentially the same. This will work toward our benefit, with better favorable outliers.
Market Data 
Markets 
AI
